Defining the Timing, Rigor, and Impact of Commercial Insights from Preclinical through Post-Launch
R&D and clinical functions take precedence in early planning, often delaying commercial involvement. This leads to missed opportunities to influence target product profile (TPP) design, trial endpoints, and payer strategy, resulting in suboptimal TPPs, overlooked market needs, and slower uptake post-launch.
The aim of this paper is to define when commercial input matters most, and what level of rigor is appropriate by development stage.
Complete the form below to access the advisory brief.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.